---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021512"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:56:17.641719+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Annexon reports Q3 2022 net loss of $35.1M, cash $269.5M; pipeline updates in Jan 2023

## Summary
- Net loss of $35.1M ($0.51 per share) vs $35.6M ($0.93 per share) in Q3 2021.
- Cash & equivalents $269.5M as of Sep 30, 2022; runway into H2 2025.
- R&D expenses $27.9M and G&A $8.2M, both essentially flat year-over-year.
- Portfolio updates across autoimmune, neurodegeneration and ophthalmology franchises planned for Jan 2023.
- ANX005 HD Phase 2 data shows reduced neuroinflammation; regulator engagement by year-end; ANX007 GA Phase 2 data expected H1 2023.

## SEC filing metadata
- accession: 0000950170-22-021512
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/0000950170-22-021512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/annx-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021512
- JSON: https://secwatch.observer/filing/0000950170-22-021512.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021512.txt

## Key facts
- Earnings Releases
  Annexon, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $35.1 million or $0.51 per share for the quarter ended September 30, 2022, EPS $0.51 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss was $35.1 million or $0.51 per share for the quarter ended September 30, 2022
  - EPS: $0.51 per share
  - Result: reported results
  source text: Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported third quarter 2022 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/0000950170-22-021512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.